Abstract
Nemus Bioscience has picked the controlled-substance manufacturing specialist Noramco to scale up production of cannabidiol-valine-hemisuccinate, a cannabidiol analog Nemus licensed from the University of Mississippi. The biotech firm says the analog is more bioavailable than cannabidiol as a treatment for ocular diseases. Meanwhile, Nemus hopes this year to begin clinical trials of a related product, tetrahydrocannabinol-valine-hemisuccinate, licensed from UM and produced by Albany Molecular Research for treating glaucoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
